End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
5.96 BGN | +0.68% | +1.02% | +4.20% |
May. 30 | Sopharma AD Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Feb. 29 | Sopharma AD Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Business Summary
Number of employees: 4,721
Sales per Business
BGN in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Pharmaceutical Goods
83.1
%
| - | - | 1,558 | 83.1 % | - |
Pharmaceutical Finished Products
16.9
%
| - | - | 317 | 16.9 % | - |
Sales per region
BGN in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Bulgaria
100.0
%
| 1,202 | 72.3 % | 1,874 | 100.0 % | +55.97% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Ognian Donev
CEO | Chief Executive Officer | 40 | 00-09-30 |
Boris Borisov
DFI | Director of Finance/CFO | - | 01-12-31 |
Ivaylo Mechev
ADM | Chief Administrative Officer | - | - |
Chief Tech/Sci/R&D Officer | - | - | |
Ivan Badinski
BRD | Director/Board Member | - | - |
Investor Relations Contact | - | - | |
Maya Taseva
HRO | Human Resources Officer | - | - |
Lora Dicheva
SAM | Sales & Marketing | - | - |
Galina Angelova
LAW | General Counsel | - | - |
S. Katzarova
LAW | General Counsel | - | - |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Ognian Donev
CEO | Chief Executive Officer | 40 | 00-09-30 |
Bisera Lazarova
BRD | Director/Board Member | - | - |
Director/Board Member | 61 | 99-12-31 | |
Director/Board Member | 59 | 11-07-11 | |
Ivan Badinski
BRD | Director/Board Member | - | - |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 179,100,063 | 55,260,634 ( 30.85 %) | 14,328,336 ( 8.000 %) | 30.85 % |
Holdings
Name | Equities | % | Valuation |
---|---|---|---|
SOPHARMA PROPERTIES REIT 40.03% | 8,787,132 | 40.03% | 46,705,452 $ |
SOPHARMA AD 7.87% | 14,087,998 | 7.87% | 45,854,743 $ |
DOVERIE UNITED HOLDING AD 25.00% | 5,374,600 | 25.00% | 26,211,118 $ |
Company contact information
Group companies
Name | Category and Sector |
---|---|
Medical Distributors
| |
Unipharm AD
Unipharm AD Pharmaceuticals: MajorHealth Technology Unipharm AD engages in the development, manufacture and sale of medicinal products. Its products include solid and liquid dosage forms and concentrates for hemodialysis. The company was founded on March 17, 1994 and is headquartered in Sofia, Bulgaria. |
Pharmaceuticals: Major
|
Medical Specialties
|
Sector
Sales per Business
Sales per region
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+4.20% | 590M | |
-58.67% | 9.31B | |
-47.19% | 8.43B | |
-26.42% | 6.36B | |
-4.69% | 6.15B | |
+92.25% | 5.17B | |
-2.63% | 4.63B | |
+3.34% | 4.41B | |
-29.24% | 3.94B | |
+6.08% | 3.05B |
- Stock Market
- Equities
- SFA Stock
- Company Sopharma AD